Is GERD a Factor in Osteonecrosis of the Jaw? Evidence of Pathology Linked to G6PD Deficiency and Sulfomucins
- PMID: 27773962
- PMCID: PMC5059643
- DOI: 10.1155/2016/8376979
Is GERD a Factor in Osteonecrosis of the Jaw? Evidence of Pathology Linked to G6PD Deficiency and Sulfomucins
Abstract
Osteonecrosis of the jaw (ONJ), a rare side effect of bisphosphonate therapy, is a debilitating disorder with a poorly understood etiology. FDA's Adverse Event Reporting System (FAERS) provides the opportunity to investigate this disease. Our goals were to analyze FAERS data to discover possible relationships between ONJ and specific conditions and drugs and then to consult the scientific literature to deduce biological explanations. Our methodology revealed a very strong association between gastroesophageal reflux and bisphosphonate-induced ONJ, suggesting acidosis as a key factor. Overgrowth of acidophilic species, particularly Streptococcus mutans, in the oral microbiome in the context of insufficient acid buffering due to impaired salivary glands maintains the low pH that sustains damage to the mucosa. Significant associations between ONJ and adrenal insufficiency, vitamin C deficiency, and Sjögren's syndrome were found. Glucose 6 phosphate dehydrogenase (G6PD) deficiency can explain much of the pathology. An inability to maintain vitamin C and other antioxidants in the reduced form leads to vascular oxidative damage and impaired adrenal function. Thus, pathogen-induced acidosis, hypoxia, and insufficient antioxidant defenses together induce ONJ. G6PD deficiency and adrenal insufficiency are underlying factors. Impaired supply of adrenal-derived sulfated sterols such as DHEA sulfate may drive the disease process.
Figures


Similar articles
-
A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.Clin Ther. 2007 Aug;29(8):1548-58. doi: 10.1016/j.clinthera.2007.08.008. Clin Ther. 2007. PMID: 17919538 Review.
-
Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.Urol Nurs. 2016 May-Jun;36(3):111-6, 154. Urol Nurs. 2016. PMID: 27501591 Review.
-
Bisphosphonate-associated osteonecrosis of the jaw: a key role of inflammation?Bone. 2009 Nov;45(5):843-52. doi: 10.1016/j.bone.2009.07.011. Epub 2009 Jul 22. Bone. 2009. PMID: 19631301
-
Msx-1 is suppressed in bisphosphonate-exposed jaw bone analysis of bone turnover-related cell signalling after bisphosphonate treatment.Oral Dis. 2011 May;17(4):433-42. doi: 10.1111/j.1601-0825.2010.01778.x. Epub 2011 Mar 2. Oral Dis. 2011. PMID: 21366807
-
Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia.J Oral Maxillofac Surg. 2007 Mar;65(3):415-23. doi: 10.1016/j.joms.2006.10.061. J Oral Maxillofac Surg. 2007. PMID: 17307586
Cited by
-
Bisphosphonate-incorporated coatings for orthopedic implants functionalization.Mater Today Bio. 2023 Jul 22;22:100737. doi: 10.1016/j.mtbio.2023.100737. eCollection 2023 Oct. Mater Today Bio. 2023. PMID: 37576870 Free PMC article. Review.
-
Increased risk of bisphosphonate-related osteonecrosis of the jaw in patients with Sjögren's syndrome: nationwide population-based cohort study.BMJ Open. 2019 Feb 13;9(2):e024655. doi: 10.1136/bmjopen-2018-024655. BMJ Open. 2019. PMID: 30765404 Free PMC article.
-
Are medication-induced salivary changes the culprit of osteonecrosis of the jaw? A systematic review.Front Med (Lausanne). 2023 Aug 31;10:1164051. doi: 10.3389/fmed.2023.1164051. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37720502 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous